Skip to main content
Figure 2 | Molecular Neurodegeneration

Figure 2

From: The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Figure 2

Mutant huntingtin and everolimus decrease S6 kinase phosphorylation in mouse HD brain. High (20 μmol/kg) but not low (10 μmol/kg) dose everolimus significantly decreases phosphorylation of S6 kinase at the S235-236 epitopes in cortex (A) and striatum (B). High-dose everolimus also significantly decreases phosphorylation of S6-kinase at the S240-244 epitopes in cortex (C) and striatum (D). S6 kinase phosphorylation at S235-236 is decreased in vehicle-treated HD compared to wild-type mice (A). Mice were treated from 4-12 weeks and sacrificed 4 hours after the last dose. X-axes show genotype-dose combinations. TG = transgenic, WT = wild-type. n = 10. p-values: * = < 0.05, ** = < 0.01

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326